DEVELOPMENT OF TRANSITION-STATE MIMETIC HIV PROTEASE INHIBITORS

一些潜在有用的方法用于治疗获得性 免疫缺陷综合症（艾滋病）及其相关疾病已经出现。 使用2 '，3'-双脱氧核苷酸家族，如 3 '-叠氮基-2'，3 '-双脱氧胸苷（AZT或齐多夫定）、2'，3 '-双脱氧胞苷 (ddC或扎西他滨）和2 '，3'-双脱氧肌苷（ddI或去羟肌苷）， 靶向人类免疫缺陷病毒I型逆转录酶 艾滋病的病原体HIV-1就是这样一种方法。 艾滋病毒也 编码一种病毒特异性天冬氨酸蛋白酶， 复制的 HIV蛋白酶介导的关键蛋白水解过程， 病毒复制后期的病毒蛋白前体。 因此，HIV蛋白酶也代表了HIV蛋白酶的病毒特异性靶标。 治疗HIV感染。

A number of potentially useful approaches for the therapy of acquired immunodeficiency syndrome (AIDS) and its related diseases have emerged. The use of family of 2',3'-dideoxynucleotides, such as 3'-azido-2',3'-dideoxythymidine (AZT or zidovudine), 2',3'dideoxycytidine (ddC or zalcitabine), and 2',3'-dideoxyinosine (ddI or didanosine), which target the reverse transcriptase of human immunodeficiency virus type I (HIV-1), the causative agent of AIDS, is one such approach. HIV also codes a virus-specific aspartic protease which is essential for its replication. The HIV protease mediates crucial proteolytic processing of viral protein precursors at a late stage in the replication of the virus. Thus, HIV protease also represents a virus-specific target for the therapy of HIV infections.